Human BRCA2 Antibody

Catalog # Availability Size / Price Qty
MAB2476
MAB2476-SP
Detection of Human BRCA2 by Western Blot.
3 Images
Product Details
Citations (13)
FAQs
Supplemental Products
Reviews

Human BRCA2 Antibody Summary

Species Reactivity
Human
Specificity
Detects endogenous human BRCA2.
Source
Monoclonal Mouse IgG1 Clone # 234403
Purification
Protein A or G purified from hybridoma culture supernatant
Immunogen
E. coli-derived recombinant human BRCA2
Met1-Thr200
Accession # P51587
Formulation
Lyophilized from a 0.2 μm filtered solution in PBS with Trehalose. *Small pack size (SP) is supplied either lyophilized or as a 0.2 µm filtered solution in PBS.
Label
Unconjugated

Applications

Recommended Concentration
Sample
Western Blot
0.2 µg/mL
See below
Immunohistochemistry
5-25 µg/mL
Immersion fixed paraffin-embedded sections of human breast cancer tissue

Please Note: Optimal dilutions should be determined by each laboratory for each application. General Protocols are available in the Technical Information section on our website.

Scientific Data

Western Blot Detection of Human BRCA2 antibody by Western Blot. View Larger

Detection of Human BRCA2 by Western Blot. Western blot shows lysates of Capan-1 human pancreatic adenocarcinoma cell line, HeLa human cervical epithelial carcinoma cell line, and U2OS human osteosarcoma cell line. PVDF membrane was probed with 0.2 µg/mL of Human BRCA2 Monoclonal Antibody (Catalog # MAB2476) followed by HRP-conjugated Anti-Mouse IgG Secondary Antibody (Catalog # HAF007). A specific band was detected for BRCA2 at approximately 380 kDa (as indicated). This experiment was conducted under reducing conditions and using Immunoblot Buffer Group 1.

Immunohistochemistry View Larger

BRCA2 in Human Breast Cancer Tissue. BRCA2 was detected in immersion fixed paraffin-embedded sections of human breast cancer tissue using Mouse Anti-Human BRCA2 Monoclonal Antibody (Catalog # MAB2476) at 5 µg/mL for 1 hour at room temperature followed by incubation with the Anti-Mouse IgG VisUCyte™ HRP Polymer Antibody (VC001). Before incubation with the primary antibody, tissue was subjected to heat-induced epitope retrieval using Antigen Retrieval Reagent-Basic (CTS013). Tissue was stained using DAB (brown) and counterstained with hematoxylin (blue). Specific staining was localized to cytoplasm and nuclei in epithelial cells. Staining was performed using our protocol for IHC Staining with VisUCyte HRP Polymer Detection Reagents.

Western Blot Detection of Human Human BRCA2 Antibody by Western Blot View Larger

Detection of Human Human BRCA2 Antibody by Western Blot Radioresistant IPF fibroblasts upregulate FoxM1, RAD51, and BRCA2 following exposure to radiation.a Upper, representative images showing FoxM1, RAD51, and BRCA2 protein expression in randomly selected control (n = 8) and IPF (n = 8) fibroblasts before and after 9 Gy radiation. beta -actin was used as a control. Lower, statistical analysis of FoxM1, RAD51, and BRCA2 protein expression in control and IPF fibroblasts (n = 8, each) before and after 9 Gy radiation. b Representative images and densitometry analysis of nuclear FoxM1 in control and IPF fibroblasts (n = 8, each) at 6 h after 9 Gy radiation. Lamin A/C and GAPDH were used as an internal control for nuclear and cytosolic fraction, respectively. c Changes in RAD51 mRNA expression in control and IPF fibroblasts (n = 8, each) as a function of time after 9 Gy radiation. d Changes in BRCA2 mRNA expression in control and IPF fibroblasts (n = 8) as a function of time after 9 Gy. Values are presented in mean ± SEM of fold changes compared to unirradiated control or IPF fibroblasts set at 1 fold. *: statistical significance of each protein or mRNA expression compared to unirradiated control or IPF fibroblasts at p < 0.05. e Left, control and IPF cells were irradiated with 9 Gy, and RAD51 positive cells were measured after 6 h as described in Materials and Methods. Right, statistical analysis was conducted using 3 images per each cell of 3 control or IPF fibroblasts. Scale bar indicates 50 µm. Shown is the mean fluorescence intensity (MFI) per nucleus. Values are presented in mean ± SEM of percentages compared to irradiated control fibroblasts set at 100%. Radioresistant IPF cells (high viability after 9 Gy) and radiosensitive control fibroblasts (low viability after 9 Gy) were selected for the experiment Image collected and cropped by CiteAb from the following publication (https://pubmed.ncbi.nlm.nih.gov/29789556), licensed under a CC-BY license. Not internally tested by R&D Systems.

Reconstitution Calculator

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Preparation and Storage

Reconstitution
Reconstitute at 0.5 mg/mL in sterile PBS.
Loading...
Shipping
Lyophilized product is shipped at ambient temperature. Liquid small pack size (-SP) is shipped with polar packs. Upon receipt, store immediately at the temperature recommended below.
Stability & Storage
Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 6 months, -20 to -70 °C under sterile conditions after reconstitution.

Background: BRCA2

BRCA2 is a nuclear protein that acts as a tumor suppressor. Germline mutation of BRCA2 accounts for many cases of familial breast and ovarian cancer. At the cellular level, BRCA2 is involved in homologous recombination (HR), a form of double-strand break repair. BRCA2 interacts with the Rad51 recombinase, another protein critical for HR, to preserve chromosomal integrity.

Long Name
Breast Cancer 2
Entrez Gene IDs
675 (Human)
Alternate Names
BRCA1/BRCA2-containing complex, subunit 2; BRCA2; BRCC2; breast and ovarian cancer susceptibility gene, early onset; breast cancer 2 tumor suppressor; breast cancer 2, early onset; breast cancer susceptibility protein BRCA2; breast cancer type 2 susceptibility protein; BROVCA2; FACD; FAD; FAD1; FANCB; FANCD; FANCD1Fanconi anemia, complementation group D1; Fanconi anemia group D1 protein; GLM3; PNCA2

Product Datasheets

You must select a language.

x

Citations for Human BRCA2 Antibody

R&D Systems personnel manually curate a database that contains references using R&D Systems products. The data collected includes not only links to publications in PubMed, but also provides information about sample types, species, and experimental conditions.

13 Citations: Showing 1 - 10
Filter your results:

Filter by:

  1. Expression of DNA Damage Response Markers in Early-Onset or Familial Gastric Cancers
    Authors: Kim HS, Kim JW, Hwang IG et al.
    Asian Pac. J. Cancer Prev.
  2. BRCA1-mediated dual regulation of ferroptosis exposes a vulnerability to GPX4 and PARP co-inhibition in BRCA1-deficient cancers
    Authors: Lei, G;Mao, C;Horbath, AD;Yan, Y;Cai, S;Yao, J;Jiang, Y;Sun, M;Liu, X;Cheng, J;Xu, Z;Lee, H;Li, Q;Lu, Z;Zhuang, L;Chen, MK;Alapati, A;Yap, TA;Hung, MC;You, MJ;Piwnica-Worms, H;Gan, B;
    Cancer discovery
    Species: Human
    Sample Types: Cell Lysates
    Applications: Western Blot
  3. Elevated CXorf67 Expression in PFA Ependymomas Suppresses DNA Repair and Sensitizes to PARP Inhibitors
    Authors: Jichang Han, Meng Yu, Yiqin Bai, Jianzhong Yu, Fei Jin, Chen Li et al.
    Cancer Cell
  4. Pharmacological ascorbate induces 'BRCAness' and enhances the effects of Poly(ADP-Ribose) polymerase inhibitors against BRCA1/2 wild-type ovarian cancer
    Authors: Y Ma, P Chen, JA Drisko, D Khabele, AK Godwin, Q Chen
    Oncol Lett, 2020-01-31;19(4):2629-2638.
    Species: Human
    Sample Types: Cell Lysates
    Applications: Western Blot
  5. Clinical significance of BRCA1 and BRCA2 mRNA and protein expression in patients with sporadic gastric cancer
    Authors: Hee Sung Kim, In Gyu Hwang, Hye Young Min, Yung‑Jue Bang, Woo Ho Kim
    Oncology Letters
  6. Tyrosine kinase inhibitor–induced defects in DNA repair sensitize FLT3(ITD)-positive leukemia cells to PARP1 inhibitors
    Authors: Silvia Maifrede, Margaret Nieborowska-Skorska, Katherine Sullivan-Reed, Yashodhara Dasgupta, Paulina Podszywalow-Bartnicka, Bac Viet Le et al.
    Blood
  7. FoxM1-dependent RAD51 and BRCA2 signaling protects idiopathic pulmonary fibrosis fibroblasts from radiation-induced cell death
    Authors: J Im, J Lawrence, D Seelig, RS Nho
    Cell Death Dis, 2018-05-22;9(6):584.
    Species: Human
    Sample Types: Tissue Homogenates
    Applications: Western Blot
  8. IGH/MYC Translocation Associates with BRCA2 Deficiency and Synthetic Lethality to PARP1 Inhibitors
    Authors: S Maifrede, K Martin, P Podszywalo, K Sullivan, SK Langer, R Nejadi, Y Dasgupta, M Hulse, D Gritsyuk, M Nieborowsk, LN Lupey-Gree, H Zhao, K Piwocka, MA Wasik, I Tempera, T Skorski
    Mol. Cancer Res., 2017-06-20;0(0):.
    Species: Human
    Sample Types: Cell Lysates, Whole Cells
    Applications: Flow Cytometry, Western Blot
  9. Gene expression and mutation-guided synthetic lethality eradicates proliferating and quiescent leukemia cells
    Authors: M Nieborowsk, K Sullivan, Y Dasgupta, P Podszywalo, G Hoser, S Maifrede, E Martinez, D Di Marcant, E Bolton-Gil, K Cramer-Mor, J Lee, M Li, A Slupianek, D Gritsyuk, S Cerny-Reit, I Seferynska, T Stoklosa, L Bullinger, H Zhao, V Gorbunova, K Piwocka, P Valent, CI Civin, M Muschen, JE Dick, JC Wang, S Bhatia, R Bhatia, K Eppert, MD Minden, SM Sykes, T Skorski
    J. Clin. Invest., 2017;127(6):2392-2406.
    Species: Human
    Sample Types: Cell Lysates
    Applications: Western Blot
  10. Cataloging antineoplastic agents according to their effectiveness against platinum-resistant and platinum-sensitive ovarian carcinoma cell lines
    Authors: K Ishiguro, YL Zhu, ZP Lin, PG Penketh, K Shyam, R Zhu, RP Baumann, AC Sartorelli, TJ Rutherford, ES Ratner
    J Transl Sci, 2016-03-05;2(2):117-124.
    Species: Human
    Sample Types: Cell Lysates
    Applications: Western Blot
  11. Clinical profile, BRCA2 expression, and the androgen receptor CAG repeat region in Egyptian and Moroccan male breast cancer patients
    Authors: Samuel F. Gilbert, Amr S. Soliman, Mehdi Karkouri, Meaghen Quinlan-Davidson, Ashley Strahley, Mohab Eissa et al.
    Breast Disease
  12. RAS promotes tumorigenesis through genomic instability induced by imbalanced expression of Aurora-A and BRCA2 in midbody during cytokinesis.
    Authors: Yang G, Mercado-Uribe I, Multani A, Sen S, Shih I, Wong K, Gershenson D, Liu J
    Int J Cancer, 2013-02-12;133(2):275-85.
    Species: Human
    Sample Types: Cell Lysates, Whole Cells, Whole Tissue
    Applications: IHC, Western Blot
  13. Aurora kinase A promotes ovarian tumorigenesis through dysregulation of the cell cycle and suppression of BRCA2.
    Authors: Yang G, Chang B, Yang F
    Clin. Cancer Res., 2010-04-27;16(12):3171-81.
    Species: Human
    Sample Types: Cell Lysates, Whole Cells, Whole Tissue
    Applications: ICC, IHC, IHC-P, Western Blot

FAQs

  1. Where do you observe staining when using Human BRCA2 antibody, Catalog # MAB2476, in IHC?

    • Human BRCA2 staining may be observed in both the nucleus and cytoplasm.

View all Antibody FAQs
Loading...

Reviews for Human BRCA2 Antibody

There are currently no reviews for this product. Be the first to review Human BRCA2 Antibody and earn rewards!

Have you used Human BRCA2 Antibody?

Submit a review and receive an Amazon gift card.

$25/€18/£15/$25CAN/¥75 Yuan/¥2500 Yen for a review with an image

$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image

Submit a Review